RadNet to Host Free Prostate Cancer Webinar on September 19, 2026

RadNet will offer a free expert-led prostate cancer education webinar with live Q&A for the public on September 19, 2026.

Rhea-AI Summary

RadNet (RDNT) will host a free public prostate cancer webinar on Saturday, September 19, 2026, featuring clinical experts and a cancer survivor.

The online event, titled “Let’s Talk About It: Prostate Cancer: Your Questions Answered,” will cover prostate cancer risk factors, screening, diagnosis, treatment options and life after cancer. Panelists include a radiologist, a urologist and robotic surgeon, and a prostate cancer survivor who used RadNet’s Enhanced Prostate Screening, which combines prostate MRI with AI. The session will also address the role of prostate MRI in guiding targeted biopsies and include a live Q&A where attendees can submit questions.

Key Terms

prostate-specific antigen, prostate mri, active surveillance, mammography

4 terms

prostate-specific antigen medical

"what may happen following an elevated prostate-specific antigen (PSA) test"

A protein made by the prostate that is measured in a blood test to help detect and monitor prostate conditions, including cancer and benign enlargement. Think of it as a dashboard gauge for prostate health: changes in the level can influence demand for diagnostics, treatments, and screenings, so shifts in how the test is used or interpreted, or news about therapies tied to it, can affect companies and investor expectations.

prostate mri medical

"how advances in prostate MRI and other imaging technologies are informing diagnosis"

Prostate MRI is a detailed, noninvasive imaging scan that creates clear pictures of the prostate gland to detect tumors, inflammation, or other abnormalities—think of it as a high-resolution map doctors use to find trouble spots. It matters to investors because wider use, better scanners, or improved interpretation software can change demand for medical equipment, diagnostic services, and reimbursed procedures, affecting revenue and regulatory risk across healthcare and med‑tech companies.

active surveillance medical

"from active surveillance to surgery and other therapies"

Active surveillance is a medical approach where a patient’s condition is closely monitored over time instead of starting immediate treatment, with therapy begun only if the condition shows signs of progression. For investors, this matters because it affects demand for drugs, diagnostics and follow-up services: a shift toward monitoring can increase sales of tests and imaging while delaying or reducing uptake of aggressive treatments, similar to choosing regular checkups instead of an immediate repair for a minor car issue.

mammography medical

"women ages 50 to 74 who were up to date with mammography"

A mammography is an X‑ray examination of breast tissue used to detect tumors, calcifications or other changes before symptoms appear. For investors, mammography matters because changes in screening technology, regulatory approvals, insurance coverage or public health guidelines directly influence demand for imaging equipment, diagnostic services and related supplies — much like how a new smartphone design can shift sales for phone makers and component suppliers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Public event brings together a radiologist, urologist and robotic surgeon, and a prostate cancer survivor for an informative conversation and live Q&A about prostate cancer screening, diagnosis and treatment

LOS ANGELES, Sept. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 outpatient imaging centers and a premier developer of radiology digital health solutions, today announced it will host a free webinar for patients and the general public on Saturday, September 19, 2026, in support of Prostate Cancer Awareness Month.

Titled “Let’s Talk About It: Prostate Cancer: Your Questions Answered,” the webinar brings together a radiologist, urologist and robotic surgeon, and a prostate cancer survivor for a candid discussion about prostate cancer risk, screening, diagnosis, treatment and life after cancer. Attendees will also have the opportunity to submit questions during a live question-and-answer session.

Besides skin cancer, prostate cancer is the most commonly diagnosed cancer among American men. Approximately one in eight men will be diagnosed during his lifetime, and an estimated 333,830 new cases will be diagnosed in the United States in 2026.¹ Although prostate and breast cancer have similar incidence and mortality rates in the United States, only 37% of men age 50 and older reported having a PSA test in the past year, compared with 80% of women ages 50 to 74 who were up to date with mammography.² Age, family history and certain inherited genetic variants can increase a man’s risk of prostate cancer. For men with a strong family history, including two or more first-degree relatives diagnosed with prostate cancer, the relative risk may be four times higher.³

The September 19th webinar will help patients and families better understand these risks, what may happen following an elevated prostate-specific antigen (PSA) test and how advances in prostate MRI and other imaging technologies are informing diagnosis and treatment planning. The webinar also will explore how prostate MRI can help physicians identify suspicious areas that may require further evaluation and support more targeted biopsy decisions for patients with elevated PSA levels.⁴

The panelists include:

• Robert Princenthal, MD, Medical Director of Prostate Imaging at RadNet, will discuss the importance of early detection, the role of prostate MRI and other imaging tools beyond the PSA test and recent advances in MRI, artificial intelligence and prostate cancer imaging.
• David Josephson, MD, urologist and robotic surgeon at Tower Urology in Los Angeles, will explain what patients can expect after an elevated PSA result and how physicians evaluate treatment options, from active surveillance to surgery and other therapies. He will also address prostate health at different ages, including risk factors, family history and genetics, and when men should begin speaking with their physicians about screening.
• Barry Katz, prostate cancer survivor, will share his personal experience, including how RadNet’s Enhanced Prostate Screening, which combines prostate MRI with AI, helped detect his cancer. He will also discuss the lessons he learned along the way and his advice for men and families navigating prostate cancer.
  
  

“Too often, men wait until there is a concern to start thinking about prostate health,” said Robert Princenthal, MD, Medical Director of Prostate Imaging, RadNet. “By making information more accessible, we can help men ask the right questions sooner and better understand when it is time to take action. My hope is that everyone who joins us leaves more confident about their next steps and is motivated to start more conversations about prostate health."

Event Details
The webinar is free to attend and open to all.

• Date: Saturday, September 19, 2026
• Time: 10-11 a.m. PDT // 1-2 p.m. EDT
• Register: www.radnet.com/webinar
  
  

About RadNet, Inc. 
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 12,000 team members. Learn more at radnet.com. 

These presentations are provided for educational and informational purposes only and do not constitute medical advice, diagnosis or treatment recommendations. Clinical decisions should be based on the independent judgment of qualified healthcare professionals, taking into account the specific circumstances of each patient.

RadNet Media Contact 
Jane Mazur 
Senior Vice President, Corporate Communications 
+1 585-355-5978 
jane.mazur@radnet.com

References

1. “Key Statistics for Prostate Cancer.” American Cancer Society. January 2026, https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html.
2. “Cancer Prevention & Early Detection Facts & Figures 2025-2026.” American Cancer Society. 2025, https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-prevention-and-early-detection-facts-and-figures/2025-cped-files/cped-cff-2025-2026.pdf.
3. Wei JT, et al., “Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.” The Journal of Urology. October 2023, https://www.auajournals.org/doi/10.1097/JU.0000000000003491.
4. “Prostate Cancer Screening (PDQ®)–Health Professional Version.” National Cancer Institute. April 2025, https://www.cancer.gov/types/prostate/hp/prostate-screening-pdq.

FAQ

Who will be speaking at RadNet’s September 19, 2026 prostate cancer webinar?

The panel will include Robert Princenthal, MD, Medical Director of Prostate Imaging at RadNet; David Josephson, MD, a urologist and robotic surgeon at Tower Urology in Los Angeles; and Barry Katz, a prostate cancer survivor who will share his personal experience with RadNet’s Enhanced Prostate Screening.

What topics will the RadNet prostate cancer webinar cover?

The webinar will address prostate cancer risk factors, screening (including PSA testing and prostate MRI), diagnosis, treatment choices from active surveillance to surgery and other therapies, prostate health at different ages, the impact of family history and genetics, and life after cancer. It will also explain how advances in MRI and artificial intelligence are being used in prostate cancer imaging and targeted biopsy decisions.

When is the webinar and how can people attend?

The webinar will take place on Saturday, September 19, 2026, from 10–11 a.m. PDT (1–2 p.m. EDT). It is free to attend and open to all. Participants can register online at www.radnet.com/webinar.

Is the information in the RadNet webinar considered medical advice?

No. The presentations are described as being for educational and informational purposes only and do not constitute medical advice, diagnosis or treatment recommendations. Clinical decisions should be made by qualified healthcare professionals based on the specific circumstances of each patient.